Cite
MLA Citation
R. Bissonnette et al.. “The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate‐to‐severe atopic dermatitis: results from a randomized double‐blind placebo‐controlled study.” British journal of dermatology, vol. 181, 2019, pp. 733–742. http://access.bl.uk/ark:/81055/vdc_100125679416.0x000060